还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

6 Z# U8 v' \# ?' l: X7 l% Z                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
: v7 @9 I* ^, }; e' L, ?4 l3 v

) @2 t, x1 N  oSub-category:
, [& n7 q& u: z1 F- x/ B- z* qMolecular Targets
' t2 Z" I  k# {
- x+ y; _: @7 V4 T/ ]6 }
Category:
, U: F. c6 C) q5 T8 WTumor Biology
! f  P* [' y* [- q

Meeting:
/ I& y. B$ p6 T0 z5 L/ n5 l2011 ASCO Annual Meeting
& V0 ~/ g* g& t2 b. A# J

Session Type and Session Title:
Poster Discussion Session, Tumor Biology
6 S. B4 t% t: k3 ]& u9 b

Abstract No:
( I! @' ?0 G( W- s10517


Citation:
2 b1 p, [  h, |# k# XJ Clin Oncol 29: 2011 (suppl; abstr 10517)
- N8 ^3 B* i! m% V" o, P2 Z
; u, X2 {6 M0 x
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


  L. D( Z: p1 t- Z" U/ `
- p- p2 x  y7 @Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

0 N8 H- N7 T7 a" |; A2 hAbstract Disclosures
* a* N. p0 t8 z
Abstract:


Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
7 k0 S0 h  J: F9 p, R# i% s3 \

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

: F8 B  B5 t5 h3 ~9 L1 {没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

3 |0 H0 |+ f' N0 ]. ]化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

% G& P# k$ Q3 H* s/ P; K平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
3 N5 e0 u6 {, N  }: I! N% K
, Z0 P# i6 d1 y# R现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊